In recent years it has become increasingly evident that excess body iron may be complicated by the supervention of hepatocellular carcinoma (HCC). Hereditary hemochromatosis (HH) was the first condition in which hepatic iron overload was shown to predispose to the development of HCC. The inherited predisposition to excessive absorption of dietary iron in HH is almost always the result of homozygosity of the C282Y mutation of the HFE gene, which causes inappropriately low secretion of hepcidin. HCC develops in 8-10% of patients with HH and is responsible for approximately 45% of deaths in the HCC patients. Cirrhosis is almost always present when HCC is diagnosed. Dietary iron overload is a condition which occurs in rural-dwelling Black Africans in southern Africa as a result of the consumption, over time, of large volumes of alcohol home-brewed in iron containers and having, as a consequence, a high iron content. Iron loading of the liver results and may be complicated by malignant transformation of the liver (relative risk of approximately 10.0). Accompanying cirrhosis does occur but is less common than that in HH. The development of HCC as a consequence of increased dietary iron, and the fact that it may develop in the absence of cirrhosis, has been confirmed in an animal model. Drinking water with a high iron content might contribute to the high incidence of HCC in parts of Taiwan. The metabolic syndrome [obesity, insulin resistance type 2 (or diabetes mellitus type 2), non-alcoholic fatty liver or non-alcoholic steatohepatitis] has in recent years become a major public health problem in some resource-rich countries. A link between excess body iron and insulin resistance or the metabolic syndrome has become apparent. The metabolic syndrome may be complicated by the supervention of HCC, and recent evidence suggests that increased body iron may contribute to this complication.

Keywords:
Cirrhosis, Dietary iron overload, Excess body iron, Hepatocellular carcinoma, Hereditary hemochromatosis
1.
Andrews NC: Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.
2.
Huang X: Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003;533:153-171.
3.
Toth I, Yuan L, Rogers JT, Boyce H, Bridges KR: Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells. J Biol Chem 1999;274:4467-4473.
4.
Fargion S, Valenti L, Fracanzani AL: Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis 2011;43:89-95.
5.
Toyokuni S: Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009;100:9-16.
6.
Ludwiczek S, Aigner E, Theurl I, Weiss G: Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003;101:4148-4154.
7.
Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM: Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140:98-104.
8.
McCord JM: Iron, free radicals, and oxidative injury. Semin Hematol 1998;35:5-12.
9.
Greene CM, Varley RB, Lawless MW: MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol 2013;19:5212-5226.
10.
Bali PK, Aisen P: Receptor-modulated iron release from transferrin: differential effects on N- and C-terminal sites. Biochemistry 1991;30:9947-9952.
11.
Strohmeyer G, Niederau C, Stremmel W: Survival and causes of death in hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci 1988;526:245-257.
12.
Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelsen EM, Halliday JW, Bassett ML, Powell LW: Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985;75:81-84.
13.
Powell LW, Yapp TR: Hemochromatosis. Clin Liver Dis 2000;4:211-228, viii.
14.
Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S: Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001;33:647-651.
15.
Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, Lööf L, Stål P, Wallerstedt S, Almer S, Sandberg-Gertzén H, Askling J: Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-1741.
16.
Adams PC, Speechley M, Kertesz AE: Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991;101:368-372.
17.
Haddow JE, Palomaki GE, McClain M, Craig W: Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen 2003;10:11-13.
18.
Purtilo DT, Gottlieb LS: Cirrhosis and hepatoma occurring at Boston City Hospital (1917-1968). Cancer 1973;32:458-462.
19.
Adams PC, Kertesz AE, Valberg LS: Rate of accumulation following iron depletion in heredtary hemochromatosis . Implications for venesection therapy. J Clin Gastroenterol 1993;16:207-210.
20.
Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, Consonni D, Coviello E, Conte D, Fargion S: Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology 2010;51:501-510.
21.
Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR: Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005;100:837-841.
22.
MacSween RN, Scott AR: Hepatic cirrhosis: a clinicopathological review of 520 cases. J Clin Pathol 1973;26:936-942.
23.
Kowdley KV: Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127(Suppl 1):S79-S86.
24.
Pietrangelo A: Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383- 2397.
25.
Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS: Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J Pathol 2006;208:82-90.
26.
Selby JV, Friedman GD: Epidemiologic evidence of an association between body iron stores and risk of cancer. Int J Cancer 1988;41:677-682.
27.
Turlin B, Juguet F, Moirand R, Le Quilleuc D, Loréal O, Campion JP, Launois B, Ramée MP, Brissot P, Deugnier Y: Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995;22:446-450.
28.
Blanc JF, De Ledinghen V, Bernard PH, de Verneuil H, Winnock M, Le Bail B, Carles J, Saric J, Balabaud C, Bioulac-Sage P: Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 2000;32:805-811.
29.
Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, Degos F, Valla D, Belghiti J, Degott C, Terris B: Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-204.
30.
Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, Bianchi PA, Fiorelli G, Conte D: Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-659.
31.
Gangaidzo IT, Moyo VM, Saugweme T, et al.: High prevalence of iron overload in urban Blacks in the 1990s. Gut 1999;45:278-283.
32.
Bothwell TH, Bradlow BA: Siderosis in the Bantu. A combined histopathological and chemical study. Arch Pathol 1960;70:279-292.
33.
Gordeuk VR, Boyd RD, Brittenham GM: Dietary iron overload persists in rural sub-Saharan Africa. Lancet 1986;1:1310-1313.
34.
Friedman BM, Baynes RD, Bothwell TH, Gordeuk VR, Macfarlane BJ, Lamparelli RD, Robinson EJ, Sher R, Hamberg S: Dietary iron overload in southern African rural blacks. S Afr Med J 1990;78:301-305.
35.
Bothwelll TH, Seftel HC, Jacobs P, et al: iron overloads in Bantu subjects. African iron overload. Studies on the availability of iron in Bantu beer. Am J Clin Nutr 1964;14:47-51.
36.
Bothwell TH, Isaacson C: Siderosis in the bantu. A comparison of incidence in males and females. BMJ 1962;1:522-524.
37.
Brink B, Disler P, Lynch S, Jacobs P, Charlton R, Bothwell T: Patterns of iron storage in dietary iron overload and idiopathic hemochromatosis. J Lab Clin Med 1976;88:725-731.
38.
Moyo VM, Gangaidzo IT, Gomo ZA, Khumalo H, Saungweme T, Kiire CF, Rouault T, Gordeuk VR: Traditional beer consumption and the iron status of spouse pairs from a rural community in Zimbabwe. Blood 1997;89:2159-2166.
39.
McNamara L, MacPhail AP, Mandishona E, Bloom P, Paterson AC, Rouault TA, Gordeuk VR: Non-transferrin-bound iron and hepatic dysf unc tion in A f ric an diet ar y iron overload. J Gastroenterol Hepatol 1999;14:126-132.
40.
Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, Waalen J, Vulpe C: Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003;31:305-309.
41.
McNamara L, Gordeuk VR, MacPhail AP: Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol 2005;20:1855-1858.
42.
Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, Kew MC: Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998;27:1563-1566.
43.
Gordeuk VR, McLaren CE, MacPhail AP, et al: Associations of iron overload in Africa and hepatocellular carcinoma and tuberculosis: Strachan's thesis revisited. Blood 1996; 87: 3470-3476.
44.
Moyo VM, Makunike R, Gangaidzo IT, Gordeuk VR, McLaren CE, Khumalo H, Saungweme T, Rouault T, Kiire CF: African iron overload and hepatocellular carcinoma (HA-7-0-080). Eur J Haematol 1998;60:28-34.
45.
Barry M, Scheuer PJ, Sherlock S, Ross CF, Williams R: Hereditary spherocytosis with secondary haemochromatosis. Lancet 1968;2:481-485.
46.
Chung H, Kudo M, Kawasaki T, Kitano M, Minami Y, Suetomi Y, Onda H: Hepatocellular carcinoma associated with secondary haemochromatosis in non-cirrhotic liver: a case report. Hepatol Res 2003;26:254-258.
47.
Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG: Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004;124:114-117.
48.
von Delius S, Lersch C, Schulte-Frohlinde E, Fend F, Dobritz M, Schmid RM, Eckel F: Hepatocellular carcinoma associated with hereditary hemochromatosis occurring in non-cirrhotic liver. Z Gastroenterol 2006;44:39-42.
49.
Ward RJ, Florence AL, Baldwin D, Abiaka C, Roland F, Ramsey MH, Dickson DP, Peters TJ, Crichton RR: Biochemical and biophysical investigations of the ferrocene-iron-loaded rat. An animal model of primary haemochromatosis. Eur J Biochem 1991;202:405-410.
50.
Braumann A, Wulfhekel U, Dullman J, et al: Iron overload of the bone marrow by trimethylhexanoylferrocene in rats. Act Anat (Basel) 1992; 144: 285-295.
51.
Deugnier YM, Guyader D, Crantock L, Lopez JM, Turlin B, Yaouanq J, Jouanolle H, Campion JP, Launois B, Halliday JW, et al: Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993;104:228-234.
52.
Jüngst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, Schramel P, Schirmacher P, Sauerbruch T, Caselmann WH: Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 2004;39:1663-1672.
53.
Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K: Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology 2006;219:41-52.
54.
Benhar M, Engelberg D, Levitzki A: Reactive oxygen stress, stress-activated kinases and stress signalling in cancer. EMBO Rep 2002;3:420-425.
55.
Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA: 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G--T and A--C substitutions. J Biol Chem 1992;267:166-172.
56.
Shyu HJ, Lung CC, Ho CC, Sun YH, Ko PC, Huang JY, Pan CC, Chiang YC, Chen SC, Liaw YP: Geographic patterns of hepatocellular carcinoma mortality with exposure to iron in groundwater in Taiwanese population: an ecological study. BMC Public Health 2013;13:352-359.
57.
World Health Organization (WHO): Iron in drinking water. Background document for development of WHO Guidelines for Drinking Water Quality. World Health Organization, 1996.
58.
Bray GA: The Metabolic Syndrome and Obesity. Humana Press, 2007.
59.
Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-1832.
60.
Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300-4308.
61.
Pietrangelo A: Iron in NASH, chronic liver diseases and HCC: how much iron is too much? J Hepatol 2009;50:249-251.
62.
Mendler MH, Turlin B, Moirand R, et al: Close association between insulin-resistance and non-alcoholic steatohepatitis. Gastroenterology 1999;117:1155-1163.
63.
Fernández-Real JM, López-Bermejo A, Ricart W: Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-2354.
64.
George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW: Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
65.
Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R: Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steatohepatitis. J Hepatol 2009;50:351-357.
66.
Pietrangelo A: Metals, oxidative stress and hepatic fibrogenesis. Sem Liv Dis 1996;16:13-30.
67.
Bugianesi E, Manzini P, D'Antrico S, et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepat 2004;39:179-187.
68.
Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S: Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251-1258.
69.
DiBisceglie AM, Axiotus CA, Hoofnagle JH, et al: Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:108-113.
70.
Hori WH, Schmidt A. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C infection. Nephrol Dial Transplant 2013 (e pub).
71.
Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.
72.
Emerit J, Beaumont C, Trivin F: Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 2001;55:333-339.
73.
Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the USA. Ann Intern Med 2000;133:592-599.
74.
Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J: Iron overload and co-factors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J Gastroenterol 2007;13:4699-4706.
75.
Saito H, Fujimoto Y, Ohtake T, Suzuki Y, Sakurai S, Hosoki Y, Ikuta K, Torimoto Y, Kohgo Y: Up-regulation of transferrin receptor 1 in chronic hepatitis C: Implication in excess hepatic iron accumulation. Hepatol Res 2005;31:203-210.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.